Abstract Antimonial compounds have been used for more than a century in the treatment of the parasitic disease leishmaniasis. Although pentavalent antimonials are still first-line drugs in several developing countries, this class of drugs is no longer recommended in the Indian sub-continent because of the emergence of drug resistance. The precise mechanisms involved in the resistance of leishmania parasites to antimony are still subject to debate. It is now well documented that drug resistance in leishmania parasites is a multifactorial phenomenon involving multiple genes whose expression pattern synergistically leads to the resistance phenotype. The reduction of intracellular antimony accumulation is a frequent change observed in resistant leishmania cells; however, no comprehensive transport model has been presented so far to explain this change and its contribution to Leishmania resistance. The present review firstly covers the actual knowledge on the metabolism of antimonial drugs, the mechanisms of their transmembrane transport and intracellular processing in Leishmania. It further describes both the functional and molecular changes associated with Sb resistance in this organism. Possible transport models based on the actual knowledge are then presented, as well as their functional implications. Biophysical and pharmacological strategies are finally proposed for the precise identification of the transport pathways.
Abbreviations T(SH) 2 trypanothione GSH glutathione AQP1 aquaglyceroporin 1 MRPA multidrug resistance-associated protein A MRP multidrug resistance-associated protein MDR multidrug resistance MAPK mitogen-activated protein kinase TryR trypanothione reductase ODC ornithine decarboxylase γ-GCS γ-glutamylcysteine synthetase HBTF terbinafine-associated encoding gene PRT1 pterine reductase APX ascorbate-dependent peroxidase G6PDH glucose-6-phosphate dehydrogenase NT4 nucleobase transporter
Introduction
The most significant clinical use of antimonial compounds during the last century is certainly that in the treatment of leishmaniasis. Leishmaniases are infective parasitic diseases, which are endemic in 98 countries, reaching up to 1.2 million new cases per year, affecting mainly poor and marginalized populations with 90 % of cases in six countries: India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia (Alvar et al. 2012) . The clinical manifestations of the complex of diseases can involve the skin, with local (cutaneous), diffuse (diffuse cutaneous) or disfiguring lesions (mucocutaneous), or the viscera (liver, spleen and bone marrow) leading to death if untreated. It is caused by parasitic protozoa belonging to the genus Leishmania, transmitted to humans via the bite of sandflies. Wild and domesticated animals, and humans themselves, can act as a reservoir of infection. The leishmania parasite is found as a motile flagellated promastigote in the sandfly gut, it diferentiates into an aflagellar amastigote when internalized by host macrophages, and resides in the acidic environment of secondary lysosomes. At the beginning of the last century, Gaspar Vianna, pioneer researcher in the treatment of leishmaniasis, reported the efficacy of trivalent antimonial drug tartar emetic for treatment of mucocutaneous leishmaniasis (Vianna 1912) . Later, the clinical use of this compound was interrupted because of their severe side effects.
From the decade of the 1940s, the less toxic, pentavalent antimony (Sb(V)) complexes, including meglumine antimoniate and sodium stibogluconate, were introduced in the therapeutics of leishmaniasis. Even though pentavalent antimonials are still the first-line drugs against all forms of leishmaniasis in several countries, their use in the clinical setting shows several limitations (Berman 1997) . These compounds have to be given parenterally, daily, for at least 3 weeks (typically, 20 mg of Sb/kg/day for 20-30 days). Antimony therapy is often accompanied by local pain during intramuscular injections and by systemic side effects, requiring very careful medical supervision.
Widespread resistance to antimonials has emerged in India, but not in Africa or South America. Therefore, antimonials are no longer recommended for treatment of leishmaniasis in the Indian sub-continent (Guerin et al. 2002; Matlashewski et al. 2011) . A hypothesis to explain the emergence of resistance in this specific region of India refers to the role of arsenic in drinking water (Perry et al. 2011) . Since 2003, the Government of India implemented several strategies to eradicate leishmaniasis as part of the kala-azar elimination program (Dhillon et al. 2008) including the use of amphotericin B and oral drug miltefosine to treat visceral leishmaniasis (Matlashewski et al. 2011) . However, increased failure rate and resistant clinical isolates against these drugs have recently been found (Sundar et al. 2012; Das et al. 2013; Purkait et al. 2012) . To subvert this scenario, drug combination has emerged as a useful strategy for leishmaniasis chemotherapy (Sundar et al. 2011; Meheus et al. 2010; Sundar et al. 2008 ); however, drug-combined resistant parasites were already selected in vitro (Garcia-Hernandez et al. 2012) , putting in doubt the efficacy of long-term exposition to drug combinations.
Studies concerning experimental resistance to antimony in Leishmania indicate that several mechanisms may occur concurrently in the same parasite and that different mechanisms may operate in field isolates compared to laboratory-selected resistant leishmania lines (Croft et al. 2006; Decuypere et al. 2012; Ouellette et al. 2004 ). On the other hand, some features observed in in vitro studies have also been demonstrated in field isolates (Mukherjee et al. 2007; Decuypere et al. 2005; Kumar et al. 2012; Kazemi-Rad et al. 2013; Rai et al. 2013; Berg et al. 2013) The overexpression of the ABC transporter multidrug resistance-associated protein A (MRPA), identified in intracellular vesicular membranes, is a common change observed in both field isolates and laboratory-selected leishmania strains resistant to antimony (Dey et al. 1994; Legare et al. 2001; Mukherjee et al. 2007; Decuypere et al. 2005; Rai et al. 2013) . Furthermore, resistance to antimony in Leishmania usually involves a reduction in its intracellular accumulation (Brochu et al. 2003) . However, attempts to characterize the transport pathways in resistant strains overexpressing the MRPA transporter showed apparently conflicting results, with either increased efflux (Dey et al. 1994) or decreased influx of trivalent antimony Sb(III) (Callahan et al. 1994) . In this context, no comprehensive transport model has been presented so far to explain the reduced drug accumulation and its participation in Leishmania resistance.
In order to address the possible transport mechanisms that may account for the reduced intracellular accumulation of antimony in resistant strains, the present review first covers the actual knowledge on the metabolism of antimonial drugs, the mechanisms of transmembrane transport and intracellular processing of antimonial drugs in leishmania cells and both functional and molecular changes associated with Sb transport in resistant strains. The final part describes possible transport models based on the present knowledge and their functional implications. Biophysical and pharmacological strategies are also proposed for the precise identification of the transport pathways.
Metabolism of antimonial drugs, mechanisms of transmembrane transport and intracellular processing in Leishmania Figure 1 summarizes the actual knowledge on the metabolism of antimonial drugs, the transport pathways identified for antimony and its intracellular processing in Leishmania.
Reduction of Sb(V) or release of Sb(III)
The metabolism and mechanism of action of pentavalent antimonials against leishmania parasites are not fully understood (Frezard et al. 2009 ). It is generally assumed that Sb(V) behaves as a prodrug that is reduced within the organism into the more toxic and active trivalent form. This model is supported by several reports that Sb(V) is reduced into Sb(III) in the vertebrate host and that reduction could also happen in the parasite (Goodwin and Page 1943; Shaked-Mishan et al. 2001; Ferreira et al. 2003; Wyllie and Fairlamb 2006; Hansen et al. 2011) . However, the exact microenvironment where the reduction occurs is still an open question.
Leishmania promastigote forms are insensitive to Sb(V), with exception of the non-pathogenic to humans L. tarentolae (Brochu et al. 2003) . On the other hand, axenically cultured amastigote-like parasites are sensitive to pentavalent antimonials, suggesting the occurrence of intracellular Sb(V) reduction in this life-cycle stage (Sereno et al. 1998) . However, in the latter case, thiol availability from the culture medium, and low pH as well as high temperature may also be determinant factors in Sb(V) to Sb(III) reduction and consequently high sensitivity to Sb(V) (Frezard et al. 2001) . Carrio et al. (2000) found that, by maintaining the pH and fetal calf serum concentration, Sb(V) activity was similar in promastigotes, intracellular amastigotes and axenic amastigote-like of L. infantum (Carrio et al. 2000) . Not only environmental factors but also stage specific development is required to reach Sb(V) sensitivity in axenically cultured amastigotes of L. donovani (Ephros et al. 1999) . Furthermore, differential Sb(V) sensitivity among different species may vary according to cellular intrinsic metabolism, membrane composition or intracellular thiol levels. The higher sensitivity of intramacrophagic amastigotes to Sb(V) compared to axenic amastigote-like favors the hypothesis of host-associated Sb(V) to Sb(III) reduction (Sereno et al. 1998) .
Thiols have been reported as potential reducing agents in this conversion (Frezard et al. 2001; Yan et al. 2003) . Reduction of Sb(V) to Sb(III) was found to occur spontaneously in the presence of the following thiols: (1) glutathione (GSH), which is the main thiol in the cytosol of mammalian cells; (2) cysteine (Cys) and cysteinyl-glycine (Cys-Gly) found predominantly within lysosomes; and (3) the bis(glutathione)-spermidine conjugate, trypanothione (T(SH) 2 ), which is the main thiol within the parasite (Fairlamb and Cerami 1992) .
The observations that Cys, Cys-Gly and T(SH) 2 are more effective reducing agents than GSH and that this reaction is favored an acidic pH (Ferreira et al. 2003) led to the hypothesis that Sb(V) may be reduced in vivo by T(SH) 2 within leishmania parasites and by Cys or Cys-Gly within the acidic compartments of mammalian cells. Both promastigotes and intracellular amastigotes maintain intracellular pH values close to neutral (~7) even in presence of extracellular acidic pH (~4-5) (Glaser et al. 1988) . This observation reinforces the hypothesis that thiol-mediated Sb(V) to Sb(III) reduction takes place preferentially in the host cell.
Other studies have suggested the participation of a parasitespecific enzymes in the process of reduction of Sb(V) to Sb(III) (Denton et al. 2004; Zhou et al. 2004 ), and also as one possible explanation for the unique Sb(V) sensitivity observed in promastigote forms of L. tarentolae (Brochu et al. 2003) . However, these parasite-specific enzymes are expressed in both life-cycle stages and therefore it is difficult to see how this would account for the differential toxicity of pentavalent antimony against promastigotes and amastigotes.
Recently, the pentavalent antimonial drug meglumine antimoniate was found to contain up to 30 % of Sb (III) indicating that the mode of action of this drug could be mediated by this residual amount of Sb(III) (Salaun and Frezard 2013) . Additionally, the availability of Sb(III) increased at reduced pH values, suggesting that this drug may act as molecular carrier releasing the active Sb(OH) 3 form specifically in the acidic intracellular compartment where leishmania parasite resides (Salaun and Frezard 2013) .
Route of antimony entry
It is now well established that Sb(III) enters leishmania cells primarily through an aquaglyceroporin named AQP1 (Gourbal et al. 2004) .
The Sb(III) transport in Leishmania through AQP1 is energy-independent (Brochu et al. 2003) . Indeed, aquaglyceroporins are known to promote the passive transport of neutral molecules such as water, glycerol and ammonia (Hub and de Groot 2008; Phongphanphanee et al. 2010 ). However, the way Sb(III) interacts with AQP1 to get inside the parasite is still an open question, but in theory it might be as the neutral Sb(OH) 3 specie, which presents molecular similarity to glycerol serving as substrate of AQP1 (Liu et al. 2002) . The crystal structure obtained of a related AQP from the malaria parasite Plasmodium falciparum, revealed a tetrameric organization of functional PfAQP (Newby et al. 2008) , which could also play a role in the selective mechanism of AQP1 (Hub and de Groot 2008) .
The differential accumulation of Sb(V) and Sb(III) in both promastigote and amastigote stages of Leishmania is the major evidence that Sb(V) uses a distinct route of entry. Indeed, competition assays using As(III), shows that Sb(III) accumulation is inhibited but not Sb(V) (Brochu et al. 2003) . Since Sb(V)-derived compounds are sugar-conjugated molecules (meglumine antimoniate and sodium stibogluconate) it has been postulated that one possible way to enter in Leishmania is via a receptor able to recognize a sugar-like structure. Brochu et al. (2003) reported an inhibition of 35 % in Sb(V) uptake by gluconate competition (Brochu et al. 2003 ). An alternative explanation for this result may be that a specific transport route exists for non-complexed Sb(V) and that added gluconate reduced the free concentration of Sb(V) in equilibrium with the Sb(V) gluconate complex.
Recently, evidence was obtained that gene deletion (Mukherjee et al. 2013) or reduced expression (Marquis et al. 2005 ) of AQP1 may result in decreased Sb(III) influx, reduced drug accumulation, and resistance.
Complexation with intracellular thiols and possible molecular targets
The antileishmanial mechanism of Sb(III) is probably related to its high affinity towards sulfhydryl-containing biomolecules, including thiols, peptides, proteins, and enzymes. Sb(III) was found to form stable complexes with the major intracellular thiols GSH and T(SH) 2 as 1:3 and 1:1 Sb-thiol species, respectively (Sun et al. 2000; Yan et al. 2003) .
Among the potential molecular targets of Sb(III), evidence was obtained that thiols, trypanothione reductase (TryR), and a zinc-finger protein may be involved. Such interaction is consistent with the modality of Cys binding of thiophilic metals such as As(III), Sb(III), and Bi(III).
It has been reported that Sb(III) interferes with the thiol metabolism by inhibiting TryR and inducing efflux of intracellular T(SH) 2 and GSH from intact leishmania cells (Wyllie et al. 2004 ). This causes oxidative stress that most probably contributes to cell death. It is worth noting that similar effects in thiol metabolism were observed with Sb(V) on axenic amastigotes in these studies.
In other recent studies, Sb(III) was found to bind to zinc finger peptide models and to promote the ejection of Zn(II) (Demicheli et al. 2008; Frezard et al. 2012) . The zinc finger domain is characterized by the coordination of a zinc atom by several amino acid residues, including cysteine and histidine. Zinc finger proteins sharing the CCHC motif have been identified in trypanosomatids and are likely to be involved in DNA replication, structure, and repair (Webb and McMaster 1993) . On the other hand, CCCH zinc finger domains which are found mainly in RNA binding proteins with regulatory functions at all stages of mRNA metabolism (Lai et al. 2002) , are suspected to play a crucial role in the biology of kinetoplastid protozoa, because of the unusual emphasis on post-transcriptional control of gene expression in this group of organisms (Clayton and Shapira 2007) . Interestingly, Sb(III) promotes Zn(II) ejection more effectively from CCCH zinc finger peptides than CCHC peptides (Frezard et al. 2012) , suggesting that the action of antimonial drugs could be related mainly to interaction of Sb(III) with CCCH zinc finger proteins.
Despite the well-accepted prodrug model, Sb(V) itself may exhibit additional antileishmania effect by host immune response modulation (Pathak and Yi 2001; Muniz-Junqueira and de Paula-Coelho 2008) and interfere with DNA dynamics (Lucumi et al. 1998) . Additionally, Sb(V)/ribonucleoside complexes may act interfering with purine transport and salvage pathway in Leishmania (Frezard et al. 2009 ).
Efflux and sequestration pathways of antimony
Once the Sb(III) is within the parasite, it can form conjugates with T(SH) 2 or GSH and the resulting complex can be extruded from the cell or sequestered into intracellular vesicles by ATP-binding cassette (ABC) transporters (Mukhopadhyay et al. 1996; Legare et al. 2001 ).
An ATP-dependent efflux activity of thiol conjugates of Sb(III) and As(III) has been identified in the plasma membrane of both As(III)-sensitive and -resistant leishmania strains (Mukhopadhyay et al. 1996; Legare et al. 2001 ). However, the responsible pump has not yet been identified. At least, it is not expected to belong to the ABCC subfamily, since ABCC proteins of Leishmania all have intracellular localization (Leprohon et al. 2009a) .
Evidence for the existence of ABC transporters in the plasma membrane of Leishmania was also obtained from functional studies using fluorescent substrates of mammalian MRP1 and Pgp pumps including calcein, pirarubicin, and rhodamine-123 and the effect of classical inhibitors such as verapamil and phenothiazines on the transport of these fluorescent markers (Sharom 2008; Essodaigui et al. 1999; Messaritakis et al. 2013 ). However, in these studies, no clear relationship between these transport pathways and antimony resistance was established. Recently, Rai et al. (2013) established for the first time the link between functional characterization of drug efflux-associated pumps and overexpression of genes previously related to Sb resistance profiling, in different Sb(V)-resistant clinically isolated L. donovani (Rai et al. 2013 ). Using fluorescent substrate for Pgp-and MRPAlike transporters, the authors highlighted the presence of these pumps in Sb(V)-resistant L. donovani field isolates together with overexpression of MRPA gene, downregulation of AQP1 and increased intracellular thiol levels associated to upregulation of thiol metabolism-related genes (Rai et al. 2013) .
A new ABC transporter, a member of the ABCI subfamily (LABCI4), capable of promoting efflux of Sb(III) and thiols, thereby conferring resistance to antimonials, has been recently identified in L. major parasites (Manzano et al. 2013 ). This transporter was located in both mitochondrial and plasma membrane. The authors postulated that LABCI4 might be a thiol-X-pump that is able to recognize metal-conjugated thiols.
The ABCC3 transporter (also known as PGPA or MRPA) was clearly identified in As(III)-and Sb(III)-resistant leishmania strains, as being located in intracellular vesicular membranes close to the flagellar pocket and evidence was obtained that this transporter presents the ability to transport thiol-conjugated metals. It has also been postulated that the MRPA-enriched vesicles may be involved in a secretion pathway that may account for reduced antimony accumulation (Legare et al. 2001) . It is also noteworthy that either decreased influx of Sb(III) or increased efflux has been reported in leishmaniaresistant mutants overexpressing MRPA (Callahan et al. 1994) . Furthermore, no correlation between the level of MRPA expression and the intracellular accumulation of Sb was observed (Papadopoulou et al. 1994) . Thus, the latter observations leave doubts about the precise transport routes involved.
It is noteworthy that overexpression of MRP1-like and Pgp-like proteins was observed not only in the parasites but also in the plasma membrane of macrophages infected with antimony-resistant L. donovani, after in vivo selection of Sb(V) resistance in hamsters (Mookerjee et al. 2008 ). This parasite-induced modulation allows the drug efflux leading to a reduced intracellular Sb(III) concentration, favoring parasite survival. Interestingly, efflux pump overexpression was not observed in Sb-sensitive Leishmania-infected macrophages (Mookerjee et al. 2008) . This evidence supports the vesiclemediated cross-talking between leishmania parasites and host cells (Silverman et al. 2010; Ghosh et al. 2013) and is a fascinating open research field for drug resistance mechanisms in leishmaniasis.
These findings taken all together indicate the possible contribution of distinct ABC transporter members and transport pathways to the drug resistance phenomenon in either field isolates or laboratory-selected leishmania mutants.
Molecular changes in antimony-resistant leishmania parasites
Unlike what happens in other drug resistant-microorganisms such as in bacteria, antimony resistance in leishmania parasites is rarely associated with single-nucleotide polymorphisms in their genome. Instead, the chromosomal plasticity allows structural changes resulting in chromosomal copy number variations and extra chromosomal DNA amplification, as revealed by whole-genome sequencing (Downing et al. 2011) . Indeed, aneuploidy is a well-documented phenomenon observed in antimony-resistant Leishmania (Ubeda et al. 2008; Leprohon et al. 2009b) . Increased gene copy number due to extra-and/or intrachromosomal amplification may contribute to the overexpression of genes resulting in metabolic adaptations that would help the parasites to survive in the presence of antimony.
The gene amplification associated with antimonial resistance phenotype usually occurs by homologous recombination of direct or inverted repeated sequences in the genome (Ouellette and Borst 1991; Beverley 1991; Grondin et al. 1996; Leprohon et al. 2009b ), leading to the formation of circular or linear extrachromosomal DNA elements (Leprohon et al. 2009b; Mukherjee et al. 2007; do MonteNeto et al. 2011) . Recently, Mukherjee et al. (2013) have demonstrated a subtelomeric intrachromosomal amplification in an Sb(III)-resistant L. major mutant. The amplified locus revealed the presence of an ascorbate-dependent peroxidase (APX) and glucose-6-phosphate dehydrogenase (G6PDH) encoding genes, which were implicated in antimonial resistance after functional analysis in a revertant mutant background (Mukherjee et al. 2013) . Since the amplification occurs at regions flanked by repeated sequences, the amplified locus in Sb-resistant Leishmania contains co-amplified genes whose direct contribution to the phenotype is often unknown. For example, the amplification of the H locus-containing MRPA also presents pteridine reductase 1 (PRT1) encoding gene and a terbinafine-associated encoding gene (HBTF) (Mukherjee et al. 2007; Marchini et al. 2003) . Table 1 presents an updated compilation of protein-coding genes frequently associated with Sb resistance phenotype, combining fold-change data in Sb-resistant Leishmania. (Rai et al. 2013) LbrM.12.0300 ≥2 (Adaui et al. 2011) Importantly, several proteins are involved directly in the transport of Sb(III), as MRPA, LABCI4, and AQP1. On the other hand, most antimony-resistance associated genes are involved in metabolic process related to oxidative stress, cell redox homeostasis, and thiol biosynthesis (Table 1) , which is not surprising considering the mode of action of antimonial drugs.
Intrinsic drug resistance mechanisms involving the transport of nutrients through the plasma membrane have been reported in Sb-resistant Leishmania. For example, the glucose transporter-encoding gene was found to be downregulated in Sb-resistant L. amazonensis (do Monte-Neto et al. 2011; Machuca et al. 2006) , suggesting a decreased formation of Lin et al., 2008 performed the assays using the Sb-related metalloid Arsenite to select (As)-resistant L. amazonensis mutants (Lin et al. 2008) reactive oxygen species as a result of reduce glucose uptake, helping the parasite to survive under the oxidative environment triggered by the drug (Machuca et al. 2006) . Similarly, the nucleobase transporter (NT4) encoding gene was found to be highly downregulated in L. amazonensis Sb-resistant mutants, although functional analysis did not confirm the role of this transporter in Sb resistance (do Monte-Neto et al. 2011) .
A change frequently observed in resistant leishmania parasites is overexpression of rate-limiting enzymes of thiol biosynthesis, such as ornithine decarboxylase (ODC) and γ-glutamylcysteine synthetase (γ-GCS), that causes an overproduction of intracellular thiols, the decrease of free intracellular Sb(III) concentration, and extra protection against the oxidative stress upon drug exposure (Grondin et al. 1997; Haimeur et al. 1999; Mukherjee et al. 2007; Mandal et al. 2007 ). The higher rate of thiol synthesis may also result in enhanced rates of efflux or sequestration of Sb-thiol conjugates through ABC transporters, contributing to the resistance phenotype (Mukhopadhyay et al. 1996; Legare et al. 2001) . In a recent metabolomic study, Berg et al. (2013) identified i n c r e a s e d l e v e l s o f m e t a b o l i t e s o f c y s t e i n e transsulfuration pathway in Sb(V)-resistant field isolates of L. donovani, indicating increased thiol production (Berg et al. 2013 ). In the same perspective, metabolites linked to the pentose phosphate pathway and NADPH production were found to be more abundant in Sbresistant parasites, suggesting that anti-oxidant processes may act against drug-induced oxidative stress (Berg et al. 2013) . Interestingly, Sb(V)-resistant L. donovani field isolates, when maintained in vitro under Sb(III) pressure, showed similar changes, as those observed at a basal level before drug addition when compared to sensitive parasites, but to a higher level in the presence of drug (Berg et al. 2013) .
ABC transporters belonging to the subfamilies ABCB, ABCC, and ABCG have been associated with drug resistance in Leishmania (Perez-Victoria et al. 2001; Haimeur et al. 2000; Coelho et al. 2003; Castanys-Munoz et al. 2007; Castanys-Munoz et al. 2008 ). Antimony resistance is often associated with upregulation of the ABCC transporter MRPA, which mediates Sb(III) detoxification, presumably by transporting the TS 2 Sb (or Sb(GS) 3 ) complexes into intracellular vesicles (Legare et al. 2001; Haimeur et al. 2000) .
More recently, a member of ABC half-transporters, LABCI4, was shown to confer 2-fold resistance to Sb(III), Sb(V), As(III), and Cd(II) when overexpressed in L. major (Manzano et al. 2013) . Unlike ABCC transporters, LABCI4 is located in both mitochondrial and plasma membranes of the parasite, and it seem to form dimers in order to perform extrusion of metal-thiol conjugates (Manzano et al. 2013 ). This transporter may be the missing piece of the puzzle that would explain the metal efflux through a thiol-X-pump in Leishmania. However, a mechanism conferring only 2-fold resistance cannot provide enough support in high resistance indexes presented by laboratory-selected Sb-resistant mutants.
As discussed above (part 2.2), Sb(III) uptake is a determinant step for the downstream drug metabolism, since this is the major known route of antimony entry into Leishmania (Gourbal et al. 2004) . When transfected into promastigote forms, the gene LmAQP1 was able to confer hypersensitivity to Sb(III) and As(III) in different Leishmania species (Gourbal et al. 2004) . Similarly, the levels of intracellular Sb can be restored in Sb(III)-resistant L. mexicana overexpressing AQP1 (Marquis et al. 2005) . A recent study has demonstrated a telomeric deletion on chromosome 31, including the AQP1 gene, in three independent Sb(III)-resistant L. major mutants. The loss of AQP1 correlates with the resistance profiling, and the mutants were still highly resistant even after 30 passages without drug pressure (Mukherjee et al. 2013) . We have recently found a similar telomeric deletion accompanied by loss of AQP1 in three out of four independent Sb(III)-resistant L. guyanensis mutants. Surprisingly, gene sequencing analysis revealed a point mutation in AQP1, from the mutant in which chromosome 31 is intact, leading to less Sb accumulation which contributes to the Sb resistance profile (Monte-Neto, Frézard and Ouellette, in preparation). Recently, Mandal et al. (2012) have shown that the mitogen-activated protein kinase (LmjMPK2) modulates LmjAQP1 function and that there is a localization switch of AQP1 (from the flagellar membrane to the entire surface of parasite) upon phosphorylation. Additionally, a deletion of MPK2 in L. mexicana leads to reduction in Sb(III) uptake when compared to wildtype parasites (Mandal et al. 2012) . On the other hand, MPK1 (encoded by gene LinJ.36.6760) was found to be upregulated in nine out of ten Indian Sb-resistant L. donovani field isolates (Kumar et al. 2012) .
Despite the strong correlation between AQP1 downregulation and antimony resistance observed in laboratory-selected mutants, data from a study performed using Sb-resistant L. donovani field isolates from India revealed an overexpression of AQP1 and reduced Sb uptake, suggesting that AQP1 may not be involved in the resistance of these clinical isolates (Maharjan et al. 2008 ). Furthermore, the expression level of genes classically associated with Sb resistance, such as MRPA, ODC, and AQP1, was not altered in promastigotes of Sbresistant L. donovani field isolates from Nepal, suggesting influence of their genetic background (Decuypere et al. 2012) . On the other hand, Sb-resistant L. donovani field isolates presented overexpression of MRPA and ODC and dowregulation of AQP1, consistent with in vitro-selected parasites profiling (Rai et al. 2013 ).
An attempt to identify genetic biomarkers for antimonial resistance phenotype in field isolates of Sb-resistant L. donovani mutants led Kumar and co-workers to conclude that there is no specific marker but multiple genes responsible for clinical resistance resulting in a "mosaic of expression pattern" (Kumar et al. 2012) . The authors recommend expression analysis of multiple genes to distinguish between Sbsensitive and -resistant isolates before treatment.
Different models for transport of Sb in resistant Leishmania cells
As illustrated in Fig. 2 , wild-type leishmania cells exhibit passive Sb(III) influx through AQP1 and actively extrude Sb-thiol conjugates via a plasma membrane pump.
The actual knowledge coming from functional and molecular studies indicates at least three possible transport models for Sb-resistant cells, which may also be combined in some mutants.
According to the "influx" model ( Fig. 2) , the efficiency of passive transport is reduced, for instance because of lower expression, deletion or mutation of AQP1. Due to the existence of active extrusion, such a change in the route of Sb(III), entry will result in a reduced intracellular accumulation of Sb. In this model, the intracellular to extracellular concentration ratio (C i /C e ) should be equal to k/(k+K e '), where k is the rate constant of passive transport and K e ' is the rate constant of active efflux. Therefore, the condition for the effective reduction of drug accumulation is: K e '>0.
According to the "efflux" model (Fig. 2) , the mutant either overexpresses the efflux pump present in the wild-type cell or expresses another additional efflux pump, so that the rate constant of active efflux (K e +K e ') becomes greater than the rate constant of influx (k). In this model, the intracellular-toextracellular concentration ratio (C i /C e ) is equal to k/(k+K e + K e '), where K e is the rate constant of active efflux by the additional transporter.
According to the "sequestration" model (Fig. 2) , sequestration of Sb(III) occurs through MRPA into intracellular vesicles and a secretion route is involved to explain the reduced intracellular accumulation. In this model, one expects the transport rate constant by MRPA (K e ) to be greater than the rate constant of passive transport (k) and the rate constant of active efflux (K e '). This implies that the rate-limiting step for Sb(III) entry into cells is the transport by AQP1, that intracellular Sb(III) is mainly located within intracellular vesicles, and that the level of Sb accumulation at steady state depends essentially on the influx-to-secretion rate constant ratio (k/ Ks e ). Moreover, secretion should be the rate-limiting step of the efflux kinetics. In an influx experiment, a pseudo-steady state is expected to be reached rapidly, characterized by constant C i , but the time-dependent increase of total intracellular Sb. In this condition, the rate of Sb(III) uptake could be influenced by MRPA. Fig. 2 Possible models of drug transport in antimony-sensitive andresistant leishmania parasites. AQP1, aquaglyceroporin 1; MRPA, multidrug resistance-associated protein A; ATe, efflux pump; C e , extracellular concentration of Sb; C i , intracellular concentration of Sb; C Si , vacuolar concentration of Sb; k, rate constant for passive transport; K e , transport rate constant by MRPA or ATe; K e ', rate constant of active efflux; Ks e , rate constant for secretion 5. Biophysical and pharmacological approaches for elucidation of Sb transport mechanisms Both biophysical and pharmacological approaches are useful to characterize functionally drug-transport mechanisms in a given cell. Typical biophysical approaches include uptake, influx and efflux studies, and the evaluation of the energydependence of the transport using metabolic inhibitor and temperature effects. Pharmacological approaches make use of competitive or non-competitive transporter inhibitor(s). In this regard, classical MRP inhibitors can be useful tools. The effect of endocytic pathways inhibitors could also be investigated. In the specific case of Sb(III) transport, the involvement of thiols in its active transport implies that inhibitors of thiol biosynthesis, such as buthionine sulfoxide (BSO), may also be helpful in the identification of the transport model. Table 2 summarizes expected biophysical and pharmacological profiles of each transport model.
According to these profiles, the systematic use of biophysical and pharmacological approaches should allow the elucidation of the precise Sb transport mechanisms.
Concluding remarks
In the present review, we covered the actual knowledge on the functional and molecular changes associated with the transport of Sb(III) in resistant leishmania cells. Thus, the scope of this review is the intrinsic resistance of the parasite to Sb(III) in the context of the well-accepted prodrug model of pentavalent antimonials, although other mechanisms of action and drug resistance have also been suggested. Thus, Sb(V) may be active by itself, for instance through immune-modulation within the macrophage. The parasite may also modulate the uptake of Sb(III) by the host cell.
Most of the actual knowledge comes from studies with axenically-cultured promastigotes selected for resistance to Sb(III), which were described extensively in this review. Importantly, this experimental model has been validated, through demonstration that these mutants were cross-resistant to Sb(V) when presented as an intracellular amastigote form. Extrapolation of the results obtained from in vitro-selected mutants to Sb-resistant clinical isolates is another critical issue. Even though some reports have presented conflicting informations about Sb resistance mechanisms between clinical isolates and in vitro-selected strains, recent studies have demonstrated an overlap of mechanisms, especially when comparison is made on equivalent resistance index.
Because of its multifactorial feature, antimony resistance in Leishmania remains a complex and challenging issue that still requires extensive investigation. It is now well established that antimony transport pathways contribute to the resistance phenotype; however, functional and molecular studies are still needed to validate the different transport models proposed in this review.
Accordingly, several gaps in knowledge can be identified, towards which future research may be directed: (1) systematic biophysical and pharmacological characterization of the transport pathways in resistant strains; (2) molecular characterization of the efflux pump(s) in the plasma membrane of Sbsensitive and -resistant strains; (3) functional and molecular characterization of the secretion route of Sb(III) in the sequestration transport model; and (4) functional and molecular characterization of the transport mechanism of Sb(V) into macrophages and amastigotes.
Utimately, all these efforts should allow not only the elucidation of the mechanisms of antimony resistance in leishmania parasites but also the design of pharmacological strategies to overcome resistance and the identification of biomarkers to predict the treatment outcomes in clinical isolates. +(↓) +(↓) -a "-" means "no"; "+" means "yes" with either a decrease (↓) or an increase (↑) b "-" when true influx rate is accessible (initial condition of uptake); "+" when influx rate is determined in condition of pseudo-steady state
